Article
The Neoantigen Landscape of the Coding and Noncoding Cancer Genome Space.
The Journal of molecular diagnostics : JMD - 1 Jun 2022
Lau Tammy T Y, Sefid Dashti Zahra J, Titmuss Emma, Pender Alexandra, Topham James T, Bridgers Joshua, Loree Jonathan M, Feng Xiaolan, Pleasance Erin D, Renouf Daniel J, Schrader Kasmintan A, Sun Sophie, Ho Cheryl, Marra Marco A, Laskin Janessa, Karsan Aly
Abstract excerpt
Tumor mutation burden (TMB) is a measure to predict patient responsiveness to immune checkpoint immunotherapy because with increased mutation frequency, the likelihood of a greater neoantigen burden is increased. Although neoantigen prediction tools exist, tumor neoantigen burden has not been adopted as a measure to predict immunotherapy response. With both measures, current guidelines are limited to the coding...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.